L₁ Terrain
The biological ground the tumour grows in — metabolic, hormonal, inflammatory
The terrain layer describes the slowly changing biological infrastructure that determines what kind of biology the tumour and the immune system must operate within. It is the generating system behind the outputs most interventions address, and the layer most relevant to the earliest phases of disease. Most relevant phases: Phase 01 (Pre-disease) · Phase 02 (Indolent) · Phase 03 (Inflection).
Most interventions act on what can be most easily measured: the outputs of biological systems. Glucose. Cholesterol. Blood pressure. Inflammatory markers. These are real, important signals, and modifying them produces real, important effects. But outputs are downstream of the systems that generate them, and acting on an output does not necessarily change the system that produced it.
Terrain is the word the QB framework uses for that generating system — the metabolic, hormonal, and inflammatory conditions that determine what kind of biology the tumour must live in. It is the biological ground. And like agricultural ground, it can be more or less hospitable to what grows in it.
Understanding terrain matters because it is the layer most relevant to the earliest phases of the disease — pre-disease, indolent, and the early inflection point — where the opportunity to shape the environment precedes and exceeds the opportunity to target any specific tumour feature.
The durability of any intervention is determined by the depth at which it acts. Terrain is the deepest layer. It strongly influences what the system tends to return to.
The problem with acting only at the surface
A drug that lowers blood glucose does not necessarily change the insulin resistance, mitochondrial dysfunction, or chronic mTOR activation that is generating the elevated glucose. It modifies the output. The generating system continues. When the drug is withdrawn, the output returns because the system that produced it was never modified.
This is the fundamental limitation of output-layer intervention, and it is not a criticism of any specific drug. It is a description of what output-layer intervention is and is not. It is a powerful and often necessary tool for managing acute pathology, reducing immediate risk, and buying time for deeper changes to occur. What it is not, on its own, is a strategy for changing what the system tends to return to when the intervention is withdrawn.
The terrain layer — what the QB framework calls the structural layer — addresses precisely this question. It acts on the slowly changing biological infrastructure that determines the baseline from which all signals emerge.
What the terrain layer acts on
The word structural is used here in the QB framework sense — meaning slowly changing biological infrastructure that determines the baseline from which outputs and signals emerge — rather than in a strict anatomical sense. The targets it describes are biologically heterogeneous: marrow architecture is genuinely anatomical, mitochondrial population quality is a quality-control process, microbiome composition is ecological, and adipose distribution is metabolic. What they share is not biological category but temporal depth and functional role: they change slowly, they are not easily captured in standard monitoring, and they strongly influence what the system tends to return to. The QB framework uses structural as a layer designation, not a biological description.
Structural modulation acts at this level: the slowly changing biological infrastructure that produces readouts. The specific targets within the QB framework are:
- Adipose tissue distribution — particularly visceral and hepatic fat, which are metabolically active in ways that subcutaneous fat is not, driving insulin resistance, inflammatory cytokine output, and aromatase activity
- Mitochondrial population quality — the proportion of functional to dysfunctional mitochondria within cells, which determines metabolic flexibility, ROS production, and signalling fidelity
- Gut microbiome architecture — the composition of microbial populations that regulate systemic inflammation, metabolic signalling, and the oestrogen-relevant entero-hepatic circulation
- Haematopoietic and lymphoid niche architecture — the bone marrow and thymic tissue systems that generate and educate the immune cells on which surveillance capacity depends
These are not readouts. They are the slowly changing infrastructure that produces readouts. Changing them is slower, harder to measure, and more consequential than changing any single marker.
Ageing as replacement of regenerative infrastructure
Before describing the specific agents that work at the terrain layer, it is worth naming the deeper pattern that connects several of its targets.
Ageing does not simply accumulate fat in random locations. Across multiple organ systems, ageing appears to progressively replace specialised regenerative tissues with adipose tissue — storage infrastructure that is metabolically active but functionally inhibitory to what it displaces:
- Active bone marrow → regulated marrow adipose tissue (rMAT): haematopoietic niche displaced and actively suppressed
- Thymic lymphoid tissue → thymic fat: T cell educational architecture lost
- Skeletal muscle → myosteatosis: contractile function replaced by intramuscular fat infiltration
- Liver parenchyma → hepatic steatosis: metabolic processing capacity degraded
The common denominator across these sites is not lipid accumulation per se but the replacement of stem-cell-dependent regenerative capacity with adipose tissue that is often inhibitory to the function it displaces. Proposed shared drivers include age-related hormonal withdrawal — particularly sex hormone decline — chronic low-grade inflammatory signalling, altered mesenchymal stem cell fate decisions, and reduced regenerative demand as physiological stress exposure declines with age.
Ageing may be partly understood as the progressive replacement of regenerative infrastructure by storage infrastructure — a shift that degrades immune competence, skeletal integrity, metabolic flexibility, and tumour surveillance through a common upstream mechanism.
This framing connects immunosenescence, osteopenia, marrow decline, sarcopenia, and metabolic disease under a single architectural concept. It positions terrain correction not merely as a local tumour microenvironment intervention but as a systemic strategy to defend regenerative tissue function across multiple organ systems simultaneously. The marrow and thymic components of this pattern are explored in detail in the haematopoietic niche section below. The full framework is developed in the QB Research Note on Aged Immune Terrain (June 2026).
The agents that work here
Pioglitazone — adipose remodelling
Pioglitazone at 7.5mg daily activates PPAR-γ, the master transcriptional regulator of adipocyte differentiation and lipid metabolism. Its primary structural effect is the redistribution of lipid away from visceral and hepatic depots toward subcutaneous storage — a shift that improves insulin sensitivity, reduces pro-inflammatory adipokine output, and reduces aromatase activity in adipose tissue. The remodelling is cumulative and occurs over months, not days. A single monitoring panel measurement will not capture it. The structural shift it produces — a different adipose architecture — determines the metabolic field conditions that all other protocol agents operate within.
Urolithin A — mitochondrial population renewal
Urolithin A drives targeted mitochondrial clearance through the PINK1–Parkin mediated mitophagy pathway. The effect is selective: mitochondria that have lost membrane potential are tagged for clearance; functional mitochondria are spared. The net result, accumulated across cycles, is a renewal of the mitochondrial population toward higher average quality. Human evidence supports molecular signatures of improved mitochondrial and cellular health; the downstream functional consequences — better metabolic efficiency, reduced ROS output, improved capacity for autophagy and cellular repair — are the inferred consequence of those signatures rather than independently demonstrated endpoints at this stage. Urolithin A is deployed in the consolidation phase (Weeks 9–10) to act on the mitochondrial population that the stress phase has prepared for clearance.
PHGG and fermented foods — microbiome architecture
Partially hydrolysed guar gum (PHGG) as a daily prebiotic and miso soup four times weekly provide the dietary substrate and microbial input that maintain gut microbiome architecture across the full cycle, including through the doxycycline alternating weeks that would otherwise disrupt the microbiome. The structural target here is not any single microbial species but the overall community composition — the balance of populations that regulate systemic inflammatory tone and the entero-hepatic cycling of oestrogen metabolites relevant to the oestrogen paper in the QB series.
Retatrutide — metabolic field maintenance and structural consequence
Retatrutide appears in both the output and structural layers of the QB framework, and that dual placement is deliberate. Its immediate effects — glucose reduction, appetite suppression, improved insulin dynamics — are output-layer events. But sustained use produces a different order of change: visceral adipose reduction, hepatic fat clearance, and systemic insulin field restoration that accumulate over months and alter the structural baseline from which all other signals emerge. The output effects are the mechanism; the structural effects are the consequence of sustaining that mechanism over time.
Its contribution to haematopoietic niche preservation operates through systemic metabolic correction rather than direct marrow intervention — reducing the upstream metabolic and inflammatory drivers of rMAT expansion. The triagonist architecture is relevant here: the glucagon, GIP, and GLP-1 arms work in concert, and the balance between them has implications for bone and marrow that are addressed in the dedicated Retatrutide paper (QB Framework Paper 13).
Haematopoietic and lymphoid niche — immune surveillance infrastructure
The four structural targets described above together constitute the slowly changing biological infrastructure the tumour must contend with. The fourth target operates by a different logic from the first three: it is the architecture of the tissues that generate immune surveillance capacity, and its degradation is invisible to standard monitoring.
The immune system does not arrive at the tumour as a finished product. It is continuously generated, educated, and maintained by two tissue systems whose quality degrades with age in ways that are directly sensitive to metabolic and inflammatory terrain: the bone marrow haematopoietic niche, which produces the cellular raw material of immune competence, and the thymic architecture, which educates T cells in the discrimination between self and other. Both are part of the regenerative infrastructure replacement pattern described above.
Terrain is not only the environment the tumour grows in. It is also the environment the immune system operates from. Both are degraded by the same upstream conditions.
Bone marrow: the generating system
Active red marrow — the haematopoietically productive tissue in the axial skeleton and proximal long bones — is progressively replaced by regulated marrow adipose tissue (rMAT) with age. This is not displacement alone. Marrow adipocytes are metabolically active and produce cytokines, fatty acids, and adipokines locally that actively suppress haematopoietic stem cell function and bias the differentiation of mesenchymal stromal cell progenitors away from osteogenic and niche-supportive fates toward further adipogenesis. The process is self-reinforcing: more marrow fat generates more suppressive local signalling, which further shifts progenitor fate, which produces more marrow fat.
The consequence for immune competence is indirect but real. rMAT expansion is associated with impaired lymphopoiesis and may contribute to reduced generation or function of T cell and NK cell lineages. The haematopoietic niche is the upstream source. Its degradation is not visible in standard monitoring, which measures peripheral cell counts rather than niche quality or lymphopoietic output. The cells may appear present; the generating capacity that will sustain them over time is the variable that is declining.
Thymus: the educational architecture
T cells acquire their functional identity in the thymus through a selection process of considerable biological severity: roughly 95 to 98 percent of thymocytes do not survive it. What emerges is a repertoire of cells capable of recognising novel threats while tolerating self tissue — the immunological definition of a functional adaptive immune system. Thymic involution begins at puberty, driven largely by sex hormone signalling, and proceeds throughout adult life. By middle age, most of the active lymphoid architecture has been replaced by fat, and the output of genuinely educated naïve T cells has contracted substantially.
The primary functional consequence of thymic involution is repertoire contraction — a narrowing of the range of antigens the immune system can recognise — rather than wholesale failure of self/other discrimination. A contracted repertoire means reduced capacity to recognise novel antigens, including tumour neoantigens. This is a terrain-level degradation of immune surveillance capacity that precedes and compounds any tumour-specific immune evasion.
An important distinction applies when evaluating interventions that appear to restore naïve T cell numbers: volume and clonal diversity are not the same thing. Even when thymic rebound produces a measurable increase in circulating naïve T cells — as occurs transiently after androgen deprivation — the breadth of the clonal repertoire those cells represent remains constrained by age-related changes in both the thymic microenvironment and the upstream haematopoietic system. The primary bottleneck is generally understood to be thymic architecture and epithelial cell function rather than absolute HSC availability, but both converge on limiting genuine de novo repertoire expansion. A surge in T cell volume that is predominantly homeostatic space-filling proliferation of existing peripheral clones does not broaden surveillance capacity in the way that genuinely renewed thymic output would. This is why structural maintenance of the marrow niche — preserving the upstream system that feeds thymic output — matters beyond any transient numerical signal.
NK cells: niche-dependent function without thymic involvement
Natural killer cells develop and undergo licensing in the bone marrow through a distinct process — KIR receptor interactions with self-MHC calibrate activation thresholds without thymic selection. But NK cell competence does not end with marrow licensing. Their functional responsiveness is continuously shaped by the peripheral stromal niche: the cytokine environment of secondary lymphoid organs, liver sinusoids, and peripheral tissues provides the IL-15 signalling required for NK cell survival and the IL-12 and IL-18 required for cytotoxic activation. These signals come from macrophages and dendritic cells whose polarisation is directly sensitive to systemic metabolic and inflammatory conditions.
In a metabolically dysregulated, chronically inflamed terrain, NK cell dysfunction is not primarily a numerical problem. The cells are present. The niche conditions that determine whether they can function are degraded. Elevated TNF-α and IL-6 suppress IL-15 signalling in stromal cells. Insulin resistance impairs the metabolic switching that NK cytotoxic activity requires. Adipose-derived leptin at chronically elevated levels is associated with reduced NK cytotoxic capacity over time. Although these relationships are supported mechanistically, direct clinical demonstration that correcting these variables restores tumour immune surveillance remains limited. The result is an immune surveillance system that looks intact on peripheral counts but is functionally attenuated by its operating environment — and whose restoration through terrain correction is biologically plausible but not yet fully established.
NK cell immune surveillance competence is not a fixed biological given. It is a dynamic output of niche quality — and niche quality is sensitive to the same metabolic and inflammatory variables that the rest of the terrain architecture addresses.
Why the existing protocol reaches this layer
None of the protocol agents target NK cells, marrow niche quality, or thymic architecture directly. This section does not propose adding any. What it establishes is that the same terrain corrections already in the protocol — visceral adipose reduction through Retatrutide, inflammatory tone reduction through metabolic normalisation, and the exercise foundation that is explicit in the QB lifestyle architecture — address the upstream conditions that drive rMAT expansion, NK niche degradation, and the metabolic insufficiency that blunts NK function.
Exercise is the clearest example. Its evidence for maintaining NK cell number and cytotoxic activity across the lifespan operates through exactly this logic: reduced visceral adiposity, lower circulating TNF-α and IL-6, improved insulin sensitivity, and a shift in peripheral macrophage polarisation toward phenotypes that produce more IL-12. Exercise is terrain correction that benefits immune surveillance as a downstream consequence, without NK cells being the stated target of any specific intervention.
In a prostate cancer context, the most instructive example of deliberate immune terrain timing is the sequencing of androgen deprivation and subsequent androgen restoration. Androgen deprivation acutely relieves androgen-receptor-mediated suppression of thymic epithelial cells, producing a transient rebound in thymic activity and naïve T cell output — a Phase 1 immune boost. But the same hormonal withdrawal simultaneously drives the rMAT expansion and mesenchymal progenitor bias described above. Prolonged deprivation allows Phase 2 terrain degradation to overtake the initial benefit: marrow niche quality declines, lymphopoiesis is associated with impairment, and the immune infrastructure the Phase 1 window briefly opened begins to erode. Protocols that exploit the Phase 1 window — timing checkpoint inhibitors, therapeutic vaccines, or androgen reintroduction through bipolar androgen therapy to the post-castration immune peak — are operating on exactly the terrain timing logic this section describes. ADT duration before intervention matters as much as the intervention itself. The full argument is developed in QB Paper 17 (Bipolar Androgen Therapy: Clinical Validation) and the companion QB Research Note on Aged Immune Terrain (June 2026).
The implication for the terrain model is that immune surveillance capacity is not a separate layer requiring separate intervention. It is a downstream beneficiary of the structural work the terrain layer already does — and, in the prostate cancer setting, a variable that protocol sequencing decisions directly shape.
Honest limitations — immune niche
The evidence for rMAT-mediated lymphopoietic impairment as a clinically meaningful driver of immune surveillance failure in prostate cancer specifically is plausible from mechanism but not yet established in direct clinical evidence. The association between marrow adipose expansion and impaired haematopoiesis is well documented; the causal chain from there to reduced tumour immune surveillance is supported by mechanistic reasoning and consistent with the broader immunosenescence literature, but has not been isolated in a clinical trial designed to test it. The claim here is that the mechanism is real, the terrain logic is coherent, and the corrections are already being made for other reasons. It is not a claim that this specific pathway has been demonstrated as a driver in this specific patient population.
Outputs can be stabilised and signals can be modulated, but it is terrain that strongly influences what the system will tend to return to. An intervention that does not reach the infrastructure layer leaves the default state largely unchanged.
QB L₁ terrain architecture — summary matrix
Terrain and the disease phases
The terrain layer is most relevant at the earliest phases of the QB framework — pre-disease (Phase 01), indolent disease (Phase 02), and the early inflection point (Phase 03). This is the window in which the environment the tumour must live in is most modifiable, before the disease has evolved the adaptive mechanisms that later phases require more direct targeting to address.
In Phase 01, the metabolic, hormonal, and inflammatory field is being set long before any diagnosis arrives. The terrain interventions here are primarily preventive: improving metabolic field conditions, reducing visceral adiposity, maintaining microbiome architecture, and preserving mitochondrial quality as the primary determinants of whether the cellular environment will permit or resist future disease.
In Phase 02, where disease is present but contained, terrain work supports the containment. The tumour in this phase is living in an environment it has not yet fully adapted to its advantage. Maintaining terrain quality — insulin sensitivity, reduced inflammatory tone, hormonal coherence — preserves the biological conditions that keep the tumour ecologically constrained.
In Phase 03, where something in the underlying biology has shifted, terrain work intersects with the signalling and selection layers. The inflection is often a metabolic event before it is a clinical event — and terrain intervention at this point is one of the earliest available responses.
How terrain interacts with the other layers
The three layers are not discrete compartments. An intervention at the terrain layer changes the conditions in which signalling-layer interventions operate, and signalling-layer interventions have terrain consequences. The relationship is continuous and bidirectional.
The most important practical implication is sequencing. Signalling-layer interventions — rapamycin, doxycycline, the hormonal coherence maintained by TRT and aromatase inhibition — operate in a metabolic environment. If that environment is characterised by chronic insulin excess, high inflammatory tone, and poor mitochondrial quality, the signalling work is done in noise. Terrain stabilisation clears the environment that the signalling work operates within.
The clear window at Weeks 11–12 is the moment when terrain expresses itself most clearly. All protocol compounds are withdrawn. The output layer returns to its true baseline. The signalling layer normalises. What remains is the terrain as it currently is — the structural baseline that the preceding cycles have been working to shift. The monitoring panel at this point is not measuring any specific drug. It is measuring the terrain.
Honest limitations
The terrain model is mechanistically grounded and clinically plausible. It is not yet the conclusion of a clinical trial designed to test this specific combination of interventions in this sequence and population. The evidence base for each individual agent is substantial; the evidence for their coordinated use as a terrain-layer architecture is not yet available.
The targets described here are biologically heterogeneous and the word structural, as used in this document, is a QB framework designation rather than a precise biological category. Readers who find the terminology imprecise are directed to the opening of the 'What the terrain layer acts on' section, which addresses this directly.
Terrain changes are slow and hard to measure. Adipose remodelling occurs over months. Mitochondrial population renewal is cumulative across cycles. Haematopoietic niche quality is not captured in standard monitoring panels. These changes do not show up cleanly in any single measurement. The absence of a visible short-term signal is not evidence of absence of effect — it is a feature of the temporal depth at which terrain-layer work operates.
DeFronzo RA. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526.
Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595–603.
Ricote M, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82.
Ambrosi TH, Schulz TJ. Adipogenic and haematopoietic niche regulation by marrow adipose tissue. Nature Reviews Endocrinology. 2021;17(7):403–416.
Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028.
Bowers E, Singer K. Obesity-induced inflammation: the role of the immune system and adipose tissue. Journal of Clinical Investigation. 2021;131(3):e168003.
Laczkó D, Oláh J, Varga I, et al. Exercise and natural killer cell function: a systematic review. Journal of Physiology. 2020;598(6):1167–1185.
Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. Journal of Pathology. 2007;211(2):144–156.
Roden CA, Bhatt VR. Marrow adipose tissue and haematopoietic stem cell niche. Current Opinion in Hematology. 2021;28(4):244–251.
Marinelli Busilacchi E, Morsia E, Poloni A. Bone marrow adipose tissue. Cells. 2024;13(9):724. doi:10.3390/cells13090724.
Zhang X, Tian L, Majumdar A, Scheller EL. Function and regulation of bone marrow adipose tissue in health and disease: state of the field and clinical considerations. Comprehensive Physiology. 2024;14(3):5521–5579. doi:10.1002/cphy.c230016.
Kousa AI, Jahn L, Zhao K, et al. Age-related epithelial defects limit thymic function and regeneration. Nature Immunology. 2024;25(9):1593–1606. doi:10.1038/s41590-024-01915-9.
Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduction and Targeted Therapy. 2023;8(1):200. doi:10.1038/s41392-023-01451-2.
Hou J, Chen A, et al. Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence. Nature Aging. 2024;4:1562–1581. doi:10.1038/s43587-024-00694-0.
Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. Journal of Immunology. 2005;175(4):2741–2753. doi:10.4049/jimmunol.175.4.2741.
This document is one of three companion pieces to Paper 08: The Three Layers of Intervention. The full paper covers all three layers in a coordinated temporal architecture. These companion pieces make each layer accessible as a standalone reading.
- L₁ Terrain — this document
- L₂ Signal — companion piece
- L₃ Selection — companion piece